دورية أكاديمية
أعرض في EDS

A metamodel-based flexible insulin therapy for type 1 diabetes patients subjected to aerobic physical activity.

التفاصيل البيبلوغرافية
العنوان: A metamodel-based flexible insulin therapy for type 1 diabetes patients subjected to aerobic physical activity.
المؤلفون: Scharbarg E; Nantes Université, École Centrale Nantes, CNRS, LS2N, UMR 6004, Nantes, F-44000, France. emeric.scharbarg@chu-nantes.fr.; Nantes Université, CHU Nantes, Department of Endocrinology, l'Institut du Thorax, Nantes, F-44000, France. emeric.scharbarg@chu-nantes.fr., Greck J; Nantes Université, École Centrale Nantes, CNRS, LS2N, UMR 6004, Nantes, F-44000, France., Le Carpentier E; Nantes Université, École Centrale Nantes, CNRS, LS2N, UMR 6004, Nantes, F-44000, France., Chaillous L; Nantes Université, CHU Nantes, Department of Endocrinology, l'Institut du Thorax, Nantes, F-44000, France., Moog CH; Nantes Université, École Centrale Nantes, CNRS, LS2N, UMR 6004, Nantes, F-44000, France.
المصدر: Scientific reports [Sci Rep] 2022 May 16; Vol. 12 (1), pp. 8017. Date of Electronic Publication: 2022 May 16.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Diabetes Mellitus, Type 1*/chemically induced , Insulin Infusion Systems*/adverse effects, Blood Glucose ; Exercise ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use
مستخلص: Patients with type 1 diabetes are subject to exogenous insulin injections, whether manually or through (semi)automated insulin pumps. Basic knowledge of the patient's characteristics and flexible insulin therapy (FIT) parameters are then needed. Specifically, artificial pancreas-like closed-loop insulin delivery systems are some of the most promising devices for substituting for endogenous insulin secretion in type 1 diabetes patients. However, these devices require self-reported information such as carbohydrates or physical activity from the patient, introducing potential miscalculations and delays that can have life-threatening consequences. Here, we display a metamodel for glucose-insulin dynamics that is subject to carbohydrate ingestion and aerobic physical activity. This metamodel incorporates major existing knowledge-based models. We derive comprehensive and universal definitions of the underlying FIT parameters to form an insulin sensitivity factor (ISF). In addition, the relevance of physical activity modelling is assessed, and the FIT is updated to take physical exercise into account. Specifically, we cope with physical activity by using heart rate sensors (watches) with a fully automated closed insulin loop, aiming to maximize the time spent in the glycaemic range (75.5% in the range and 1.3% below the range for hypoglycaemia on a virtual patient simulator).These mathematical parameter definitions are interesting on their own, may be new tools for assessing mathematical models and can ultimately be used in closed-loop artificial pancreas algorithms or to extend distinguished FIT.
(© 2022. The Author(s).)
References: J Biomech. 2008;41(4):744-52. (PMID: 18206156)
Cold Spring Harb Perspect Biol. 2014 Jan 01;6(1):. (PMID: 24384568)
Diabetologia. 2012 Mar;55(3):542-51. (PMID: 22189486)
Clin Med Insights Endocrinol Diabetes. 2019 May 03;12:1179551419844521. (PMID: 31105434)
J Diabetes Sci Technol. 2018 Jul;12(4):847-853. (PMID: 29415555)
J Diabetes Sci Technol. 2008 Jan;2(1):169-74. (PMID: 19885195)
Med Sci Sports Exerc. 2007 May;39(5):822-9. (PMID: 17468581)
Diabetes Spectr. 2015 Jan;28(1):55-62. (PMID: 25717279)
BMJ. 2002 Oct 5;325(7367):746. (PMID: 12364302)
J Diabetes Sci Technol. 2014 Jan 1;8(1):26-34. (PMID: 24876534)
J Diabetes Sci Technol. 2018 Mar;12(2):273-281. (PMID: 29451021)
PLoS One. 2019 Jul 25;14(7):e0217301. (PMID: 31344037)
Diabetes Care. 2016 Nov;39(11):2065-2079. (PMID: 27926890)
J Diabetes Sci Technol. 2007 May;1(3):338-47. (PMID: 19885088)
Am J Physiol. 1979 Jun;236(6):E667-77. (PMID: 443421)
Am J Physiol Endocrinol Metab. 2002 May;282(5):E992-1007. (PMID: 11934663)
IEEE Trans Biomed Eng. 2015 Jun;62(6):1546-52. (PMID: 25615904)
J Diabetes Sci Technol. 2018 Sep;12(5):937-952. (PMID: 30095007)
Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84. (PMID: 33298417)
PLoS One. 2021 Mar 26;16(3):e0248280. (PMID: 33770092)
Lancet Diabetes Endocrinol. 2017 Jul;5(7):501-512. (PMID: 28533136)
سلسلة جزيئية: ClinicalTrials.gov NCT04572009
المشرفين على المادة: 0 (Blood Glucose)
0 (Hypoglycemic Agents)
0 (Insulin)
تواريخ الأحداث: Date Created: 20220516 Date Completed: 20220519 Latest Revision: 20231105
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9110411
DOI: 10.1038/s41598-022-11772-x
PMID: 35577814
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-022-11772-x